Do You Have Celiac Disease and Have Questions Or Need Help?
Join Celiac.com's forum / message board and get your questions answered! Our forum has nearly 1 MILLION POSTS, and over 62,000 MEMBERS just waiting to help you with any questions about celiac disease and the gluten-free diet. We'll see you there!
Follow / Share
|Get Email Alerts|
- Safe Gluten-Free Food List (Safe Ingredients)
- Unsafe Gluten-Free Food List (Unsafe Ingredients)
- Gluten-Free Alcoholic Beverages
- Celiac Disease Symptoms
- The Gluten-Free Diet 101 - A Beginner's Guide to Going Gluten-Free
- Interpretation of Celiac Disease Blood Test Results
- Is Buckwheat Flour Really Gluten-Free?
Mayo Clinic Says New Celiac Drug Reduces GI and Non-GI Symptoms
Jefferson Adams is a freelance writer living in San Francisco. His poems, essays and photographs have appeared in Antioch Review, Blue Mesa Review, CALIBAN, Hayden's Ferry Review, Huffington Post, the Mississippi Review, and Slate among others.
He is a member of both the National Writers Union, the International Federation of Journalists, and covers San Francisco Health News for Examiner.com.View all articles by Jefferson Adams
Celiac.com 07/28/2014 - One angle being tried by researchers to treat celiac disease involves oral peptides. These are orally administered drugs that would prevent an adverse gluten reaction in people with celiac disease who are following a gluten-free diet.
The drugs are intended to prevent adverse reactions from minor gluten contamination or exposure.
In a recent update from the Mayo clinic, Joseph Murray, MD, confirms that larazotide acetate, a first-in-class oral peptide, has ”met the study's primary end point of a reduction in GI symptoms.” Dr. Murray presented the results from the study as a late-breaking abstract at Digestive Disease Week 2014.
In a celiac disease reaction, the epithelial tight junctions that control paracellular permeability are compromised, and gut permeability increases. This is partly due to an inflammatory immune response to the entrance of gluten peptides into the intestinal lamina propria through these tight junctions.
Larazotide acetate prevents tight-junction opening and reduces gluten uptake, inhibiting gluten- and cytokine-induced intestinal permeability and inflammation in vivo.
This randomized, parallel, double-blind, placebo-controlled, multicenter trial was conducted at 74 sites in North America. The aim was to evaluate the effect of larazotide acetate on GI signs and symptoms in patients with celiac disease.
Celiac.com welcomes your comments below (registration is NOT required).
Secretory Immunoglobulin A, CD71, and Transglutaminase-2 Interactions Alter Permeability of Intestinal Epithelial Cells to Gliadin Peptides
In duodenal biopsy samples from people with active celiac disease, the transferrin receptor, CD71, is up-regulated, and promotes retro-transport of secretory immunoglobulin A (SIgA)-gliadin complexes.... [READ MORE]
Can New Terms Improve Outcomes for Sub-clinical Celiac Disease and Gluten Sensitivity?
Over the last two decades, there has been a marked increase in the prevalence of celiac disease, especially the sub-clinical celiac disease forms and non-celiac gluten sensitivity.... [READ MORE]
Gluten Peptide Research Advancing Immunotherapy for Celiac Disease
Currently, one of the more promising areas of celiac disease research looks to be in peptide-based therapies.... [READ MORE]
Rod-Shaped Bacteria May Trigger Celiac Disease
Am J Gastroenterol.... [READ MORE]